The IMPROVE™ study - A multinational, observational study in type 2 diabetes: Baseline characteristics from eight national cohorts

International Journal of Clinical Practice

Volumn 62, Issue 11, 2008, Pages 1809-1819

  Valensi, P ^a,j   Benroubi, M ^b   Borzi, V ^c   Gumprecht, J ^d   Kawamori, R ^e   Shaban, J ^f   Shah, S ^g   Shestakova, M ^h   Wenying, Y ⁱ  

^a UNIVERSITÉ PARIS 13   (France)

^b KAT HOSPITAL   (Greece)

^c UNIVERSITY OF CATANIA   (Italy)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f WINDSOR REGIONAL HOSPITAL   (Canada)

^g Bhatia Hospital   (India)

^h N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

ⁱ CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^j HÔPITAL JEAN VERDIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLEXPEN; GLUCOSE; INSULIN ASPART; ORAL ANTIDIABETIC AGENT; PENFILL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DEMOGRAPHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; POSTPRANDIAL STATE; PRIORITY JOURNAL; THERAPY DELAY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DECISION MAKING; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED;

BLOOD GLUCOSE; COHORT STUDIES; DECISION MAKING; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 54049148994     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01917.x     Document Type: Article

References (28)

1. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 12.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
3. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999 16 : 716 30.
4. IDF. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels : International Diabetes Federation, 2005. http://www.idf.org/home/index.cfm?unode=B7462CCB-3A4C-472C-80E4-710074D74AD3 (accessed August 2008).
5. Bebakar WMW, Chow CC, Kadir KA et al. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 724 32.
6. Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006 114 : 527 32.
7. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
8. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003 17 : 307 13.
9. Yang W, Ji Q, Zhu D et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen without increasing hypoglycemia in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008 31 : 852 6.
10. Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007 29 : 1284 92.
11. Lüddeke H-J, Sreenan S, Aczel S et al. PREDICTIVE™- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycemia from the European cohort. Diabetes Obes Metab 2007 9 : 428 34.
12. Khutsoane D, Sharma SK, Almustafa M et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008 10 : 212 22.
13. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003 26 : 881 5.
14. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the multicultural community health assessment trial (M-CHAT). Am J Clin Nutr 2007 86 : 353 9.
15. Huxley R, James WP, Barzi F et al. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008 9 (Suppl. 1 53 61.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 : S43 8.
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008 31 (Suppl. 1 S12 54.
18. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 13 (Suppl. 1 1 66.
19. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 : 1047 53.
20. International Diabetes Federation. Diabetes Atlas. Executive Summary, 2nd edn. Brussels : International Diabetes Federation, 2003. http://www.idf.org/e- atlas (accessed August 2008).
21. Nield L, Moore HJ, Hooper L et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 2007, 3, CD004097.
22. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabetic Med 1998 15 : 290 6.
23. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? Diabetes Metab Res Rev 2007 23 : 257 64.
24. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes 2004 28 (Suppl. 2 S14 22.
25. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005 28 : 2673 9.
26. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control. J Gen Intern Med 2007 22 : 453 8.
27. Brown JB, Nichols GA. Slow response of glycemic control in type 2 diabetes mellitus. Am J Manag Care 2003 9 : 213 7.
28. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006 8 : 58 66.